MiR-365 Promotes Cutaneous Squamous Cell Carcinoma (CSCC) Through Targeting Nuclear Factor I/B (NFIB)

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2014 Jun 21

PMID 24949940

Citations 45

Authors

Meijuan Zhou

Liang Zhou

Li Zheng

Ling Guo

Yinghui Wang

Hongxia Liu

Chengshan Ou

Zhenhua Ding

Affiliations

Soon will be listed here.

Abstract

Aberrant expression of microRNAs plays vital roles in tumor development and progression. As transcription factors (TFs) are the critical components of signaling cascades, specific targeting effects of microRNAs to specific TFs may determine the role of microRNAs in different cancers. In this study, we identified Nuclear Factor I/B (NFIB) as one of the targets of miR-365 which was previously verified as an onco-miR in cutaneous squamous cell carcinoma (CSCC). Down-regulation of NFIB was a general feature in both CSCC cell lines and tumors from patients which show drastically up-regulated miR-365 expression levels. The siRNA-based knockdown of NFIB mimic the carcinogenic transformation of normal cells by ectopically expression of miR-365 which indicates depletion of NFIB is necessary for miR-365 to exert its pro-carcinogenic function. NFIB may represent a functional barrier targeted by miR-365 to the development of CSCC. Further studies also discovered a conserved feedback regulatory circuitry formed by NFIB and miR-365 in CSCC development which may be potentially utilized as therapeutic target to improve the clinical CSCC treatment.

Citing Articles

Micro RNA Dysregulation in Keratinocyte Carcinomas: Clinical Evidence, Functional Impact, and Future Directions.

Conley J, Genenger B, Ashford B, Ranson M Int J Mol Sci. 2024; 25(15).

PMID: 39126067 PMC: 11313315. DOI: 10.3390/ijms25158493.

MiRNA-224-5p regulates the defective permeability barrier in sensitive skin by targeting claudin-5.

Yang L, Wu W, Lyu L, Tu Y, Gu H, Chen X Skin Res Technol. 2024; 30(5):e13720.

PMID: 38743384 PMC: 11093069. DOI: 10.1111/srt.13720.

MicroRNA-124 plays an inhibitory role in cutaneous squamous cell carcinoma cells via targeting SNAI2, an immunotherapy determinant.

Hu X, Yan R, Jia X, Feng H, Zhang N, Chen X Heliyon. 2024; 10(3):e24671.

PMID: 38317973 PMC: 10839798. DOI: 10.1016/j.heliyon.2024.e24671.

Epigenetic reprogramming of a distal developmental enhancer cluster drives SOX2 overexpression in breast and lung adenocarcinoma.

Abatti L, Lado-Fernandez P, Huynh L, Collado M, Hoffman M, Mitchell J Nucleic Acids Res. 2023; 51(19):10109-10131.

PMID: 37738673 PMC: 10602899. DOI: 10.1093/nar/gkad734.

CircIFFO1 suppresses tumor growth and metastasis of cutaneous squamous cell carcinoma by targeting the miR-424-5p/NFIB axis.

Yu H, Liu P, Chen T Arch Dermatol Res. 2023; 315(9):2585-2596.

PMID: 37405427 DOI: 10.1007/s00403-023-02659-6.

References

Nie J, Liu L, Zheng W, Chen L, Wu X, Xu Y . microRNA-365, down-regulated in colon cancer, inhibits cell cycle progression and promotes apoptosis of colon cancer cells by probably targeting Cyclin D1 and Bcl-2. Carcinogenesis. 2011; 33(1):220-5. DOI: 10.1093/carcin/bgr245. View

Xia J, Song X, Bi Z, Chu W, Wan Y . UV-induced NF-kappaB activation and expression of IL-6 is attenuated by (-)-epigallocatechin-3-gallate in cultured human keratinocytes in vitro. Int J Mol Med. 2005; 16(5):943-50. View

Gronostajski R . Roles of the NFI/CTF gene family in transcription and development. Gene. 2000; 249(1-2):31-45. DOI: 10.1016/s0378-1119(00)00140-2. View

Kollmann K, Heller G, Schneckenleithner C, Warsch W, Scheicher R, Ott R . A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. Cancer Cell. 2013; 24(2):167-81. PMC: 3743049. DOI: 10.1016/j.ccr.2013.07.012. View

Zhou M, Liu W, Ma S, Cao H, Peng X, Guo L . A novel onco-miR-365 induces cutaneous squamous cell carcinoma. Carcinogenesis. 2013; 34(7):1653-9. PMC: 3697891. DOI: 10.1093/carcin/bgt097. View

Pjanic M, Pjanic P, Schmid C, Ambrosini G, Gaussin A, Plasari G . Nuclear factor I revealed as family of promoter binding transcription activators. BMC Genomics. 2011; 12:181. PMC: 3082249. DOI: 10.1186/1471-2164-12-181. View

Yan L, Huang X, Shao Q, Huang M, Deng L, Wu Q . MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA. 2008; 14(11):2348-60. PMC: 2578865. DOI: 10.1261/rna.1034808. View

Giglia-Mari G, Sarasin A . TP53 mutations in human skin cancers. Hum Mutat. 2003; 21(3):217-28. DOI: 10.1002/humu.10179. View

Fujita S, Ito T, Mizutani T, Minoguchi S, Yamamichi N, Sakurai K . miR-21 Gene expression triggered by AP-1 is sustained through a double-negative feedback mechanism. J Mol Biol. 2008; 378(3):492-504. DOI: 10.1016/j.jmb.2008.03.015. View

10.

Guo S, Ye H, Teng Y, Wang Y, Yang G, Li X . Akt-p53-miR-365-cyclin D1/cdc25A axis contributes to gastric tumorigenesis induced by PTEN deficiency. Nat Commun. 2013; 4:2544. PMC: 3826643. DOI: 10.1038/ncomms3544. View

11.

Meek D . Tumour suppression by p53: a role for the DNA damage response?. Nat Rev Cancer. 2009; 9(10):714-23. DOI: 10.1038/nrc2716. View

12.

Zhou L, Wang L, Lu L, Jiang P, Sun H, Wang H . Inhibition of miR-29 by TGF-beta-Smad3 signaling through dual mechanisms promotes transdifferentiation of mouse myoblasts into myofibroblasts. PLoS One. 2012; 7(3):e33766. PMC: 3306299. DOI: 10.1371/journal.pone.0033766. View

13.

Cooper S, Bowden G . Ultraviolet B regulation of transcription factor families: roles of nuclear factor-kappa B (NF-kappaB) and activator protein-1 (AP-1) in UVB-induced skin carcinogenesis. Curr Cancer Drug Targets. 2007; 7(4):325-34. PMC: 2605645. DOI: 10.2174/156800907780809714. View

14.

Persson M, Andren Y, Mark J, Horlings H, Persson F, Stenman G . Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci U S A. 2009; 106(44):18740-4. PMC: 2773970. DOI: 10.1073/pnas.0909114106. View

15.

Zhou L, Wang L, Lu L, Jiang P, Sun H, Wang H . A novel target of microRNA-29, Ring1 and YY1-binding protein (Rybp), negatively regulates skeletal myogenesis. J Biol Chem. 2012; 287(30):25255-65. PMC: 3408151. DOI: 10.1074/jbc.M112.357053. View

16.

Ziegler A, Jonason A, Leffell D, Simon J, Sharma H, Kimmelman J . Sunburn and p53 in the onset of skin cancer. Nature. 1994; 372(6508):773-6. DOI: 10.1038/372773a0. View

17.

Guo L, Huang Z, Chen X, Deng Q, Yan W, Zhou M . Differential expression profiles of microRNAs in NIH3T3 cells in response to UVB irradiation. Photochem Photobiol. 2008; 85(3):765-73. DOI: 10.1111/j.1751-1097.2008.00482.x. View

18.

Moon H, Hwang K, Kim J, Kim H, Lee M, Jung E . NFIB is a potential target for estrogen receptor-negative breast cancers. Mol Oncol. 2011; 5(6):538-44. PMC: 5528324. DOI: 10.1016/j.molonc.2011.08.002. View

19.

Juin P, Geneste O, Gautier F, Depil S, Campone M . Decoding and unlocking the BCL-2 dependency of cancer cells. Nat Rev Cancer. 2013; 13(7):455-65. DOI: 10.1038/nrc3538. View

20.

Kang S, Lee H, Cho J . MicroRNA-365 regulates NKX2-1, a key mediator of lung cancer. Cancer Lett. 2013; 335(2):487-94. DOI: 10.1016/j.canlet.2013.03.006. View